Operating Segments

9 Months Ended

12 Months Ended

Sep. 30, 2016

Dec. 31, 2015

Operating Segments [Abstract]

Operating Segments

Note 9. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	Three Months Ended September 30,
	2016			2015
Contract/Grant Revenue
Vaccines/BioDefense	$	2,959,254		$	3,879,675
BioTherapeutics		—			—
Total	$	2,959,254		$	3,879,675
Income (Loss) from Operations
Vaccines/BioDefense	$	239,012		$	653,415
BioTherapeutics		(908,086	)		(959,065	)
Corporate		(829,743	)		(964,016	)
Total	$	(1,498,817	)	$	(1,269,666	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	10,090		$	10,093
BioTherapeutics		10,313			50,673
Corporate		2,063			2,074
Total	$	22,466		$	62,840
Other Income (Expense), Net
Corporate	$	(174,400	)	$	4,044,014
Share-Based Compensation
Vaccines/BioDefense	$	25,164		$	19,344
BioTherapeutics		30,496			29,180
Corporate		61,590			86,400
Total	$	117,250		$	134,924

	Nine Months Ended September 30,
	2016			2015
Contract/Grant Revenue
Vaccines/BioDefense	$	8,750,291		$	5,781,816
BioTherapeutics		—			13,972
Total	$	8,750,291		$	5,795,788
Income (Loss) from Operations
Vaccines/BioDefense	$	1,291,123		$	1,040,627
BioTherapeutics		(2,822,766	)		(3,094,883	)
Corporate		(2,882,836	)		(2,808,428	)
Total	$	(4,414,479	)	$	(4,862,684	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	30,150		$	29,820
BioTherapeutics		31,309			148,913
Corporate		6,443			5,763
Total	$	67,902		$	184,496
Other Income (Expense), Net
Corporate	$	1,499,055		$	(909,984	)
Share-Based Compensation
Vaccines/BioDefense	$	77,393		$	63,280
BioTherapeutics		96,313			88,615
Corporate		280,229			262,217
Total	$	453,935		$	414,112

	As of September 30, 2016		As of December 31, 2015
Identifiable Assets
Vaccines/BioDefense	$	1,801,149	$	2,123,676
BioTherapeutics		56,555		76,183
Corporate		5,896,100		5,187,263
Total	$	7,753,804	$	7,387,122

Note 11. Operating Segments

The Company maintains two active operating segments: BioTherapeutics and Vaccines/BioDefense. Each segment includes an element of overhead costs specifically associated with its operations, with its corporate shared services group responsible for support functions generic to both operating segments.

	For the Years Ended December 31,
	2015			2014
Revenues
Vaccines/BioDefense	$	8,754,418		$	6,756,388
BioTherapeutics		13,972			286,628
Total	$	8,768,390		$	7,043,016
Income (Loss) from Operations
Vaccines/BioDefense	$	1,263,709		$	807,164
BioTherapeutics		(4,487,988	)		(7,674,381	)
Corporate		(3,885,997	)		(3,894,132	)
Total	$	(7,110,276	)	$	(10,761,349	)
Amortization and Depreciation Expense
Vaccines/BioDefense	$	39,925		$	39,625
BioTherapeutics		199,661			199,196
Corporate		7,872			6,966
Total	$	247,458		$	245,787
Other Income (Expense), Net
Corporate	$	(1,209,887	)	$	3,437,505
Share-Based Compensation
Vaccines/BioDefense	$	111,960		$	114,920
BioTherapeutics		148,244			193,926
Corporate		394,277			411,304
Total	$	654,481		$	720,150

	As of December 31,
	2015		2014
Identifiable Assets
Vaccines/BioDefense	$	2,123,676	$	1,025,220
BioTherapeutics		76,183		204,308
Corporate		5,187,263		5,724,720
Total	$	7,387,122	$	6,954,248